Recognition and treatment of genitourinary complications in paediatric Crohn’s disease using Infliximab
Article first published online: 23 FEB 2010
© 2010 The Author(s)/Journal Compilation © 2010 Foundation Acta Pædiatrica
Volume 99, Issue 7, pages 1042–1046, July 2010
How to Cite
Afzal, N., Shenoy, M., Haque, S., Wilcox, D. and Shah, N. (2010), Recognition and treatment of genitourinary complications in paediatric Crohn’s disease using Infliximab. Acta Paediatrica, 99: 1042–1046. doi: 10.1111/j.1651-2227.2010.01731.x
- Issue published online: 1 JUN 2010
- Article first published online: 23 FEB 2010
- Received 30 November 2009; revised 29 December 2009; accepted 21 January 2010.
- Crohn’s disease;
- Inflammatory bowel disease;
- Urinary tract
Although genitourinary complications of Crohn’s are well recognized, available information regarding their clinical course and management is sparse especially in the paediatric population. We report a myriad of urological complications in five paediatric cases, our experience from a tertiary paediatric urological and gastroenterological centre. All children with urological complications had severe Crohn’s disease which necessitated the use of immuno-suppressants including Infliximab. Three of four children healed and closed their fistulas after treatment, although failed to avoid future surgery, albeit for other reasons.
Conclusion: We suggest Infliximab should be considered as a treatment option but in the absence of a common consensus, treatment be tailored to individual cases.